Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
eBay
EBAY
5
Halozyme Therapeutics
HALO
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 61.32%63.71M | 17.45%11.28M | 107.05%289K | 107.40%941K | 9.62%51.2M | -97.50%39.49M | -55.93%9.6M | -101.10%-4.1M | 70.20%-12.72M | -96.20%46.71M |
Operating revenue | 61.32%63.71M | 17.45%11.28M | 107.05%289K | -10.97%941K | 9.62%51.2M | -97.50%39.49M | -55.93%9.6M | -101.10%-4.1M | 102.48%1.06M | -96.20%46.71M |
Cost of revenue | -69.44%845K | -14.29%684K | 31.58%50K | 136.36%52K | -96.91%59K | -98.11%2.77M | -86.69%798K | -99.83%38K | -99.92%22K | -97.88%1.91M |
Gross profit | 71.16%62.87M | 20.33%10.59M | 105.78%239K | 106.98%889K | 14.15%51.15M | -97.44%36.73M | -44.25%8.8M | -101.18%-4.14M | 81.95%-12.74M | -96.07%44.81M |
Operating expense | -13.07%615.04M | -7.91%131.69M | 22.10%218.83M | -32.39%133.24M | -30.26%131.23M | 17.70%707.48M | -14.01%143M | 16.22%179.22M | 27.46%197.08M | 49.39%188.18M |
Selling and administrative expenses | -31.76%119.03M | -35.22%26.7M | -37.11%25.74M | -33.50%30.27M | -22.46%36.27M | 7.84%174.44M | 6.39%41.22M | -5.19%40.93M | 9.43%45.51M | 22.28%46.78M |
Research and development costs | -12.63%506.5M | -2.65%106.08M | 34.58%195.18M | -37.46%105.11M | -36.49%100.13M | 22.14%579.72M | -29.78%108.97M | 27.03%145.03M | 46.05%168.08M | 74.72%157.64M |
Other operating expenses | 77.52%-10.49M | 84.75%-1.1M | 68.96%-2.09M | 87.08%-2.13M | 68.16%-5.17M | -32.16%-46.69M | 73.99%-7.19M | -115.58%-6.74M | -702.67%-16.52M | -544.39%-16.25M |
Operating profit | 17.68%-552.17M | 9.76%-121.09M | -19.21%-218.59M | 36.92%-132.36M | 44.14%-80.08M | -180.52%-670.75M | 10.84%-134.2M | -194.05%-183.36M | 6.84%-209.82M | -114.14%-143.37M |
Net non-operating interest income expense | -17.45%71.81M | -31.75%14.15M | -20.08%17.53M | -18.12%18.85M | -0.11%21.28M | 209.66%86.99M | 28.22%20.74M | 135.01%21.93M | 946.18%23.02M | 5,391.49%21.31M |
Non-operating interest income | -17.45%71.81M | -31.75%14.15M | -20.08%17.53M | -18.12%18.85M | -0.11%21.28M | 209.66%86.99M | 28.22%20.74M | 135.01%21.93M | 946.18%23.02M | 5,391.49%21.31M |
Other net income (expense) | 3.81%-42.74M | 131.05%2.27M | -140.04%-12.48M | -143.84%-26.38M | 70.64%-6.2M | 58.42%-44.44M | 57.83%-7.3M | -138.68%-5.2M | -1.12%-10.82M | 77.12%-21.12M |
Gain on sale of security | 74.74%-5.53M | -18.15%-1.17M | 141.74%1.13M | 108.43%429K | 54.86%-5.92M | 80.31%-21.89M | -111.17%-992K | 80.08%-2.71M | 55.35%-5.09M | 86.21%-13.1M |
Special income (charges) | -158.09%-35M | 181.81%3.94M | -276.99%-12.71M | -389.66%-26.28M | ---- | ---13.56M | ---4.82M | ---3.37M | ---5.37M | ---- |
-Less:Restructuring and merger&acquisition | 158.09%35M | -181.81%-3.94M | 276.99%12.71M | 389.66%26.28M | ---- | --13.56M | --4.82M | --3.37M | --5.37M | ---- |
Other non- operating income (expenses) | 75.30%-2.22M | 65.93%-506K | -201.25%-893K | -45.78%-535K | 96.42%-287K | -311.06%-8.99M | 94.33%-1.49M | -96.74%882K | -153.11%-367K | -393.81%-8.02M |
Income before tax | 16.73%-523.11M | 13.32%-104.68M | -28.16%-213.54M | 29.21%-139.89M | 54.61%-65M | -183.28%-628.19M | 20.36%-120.76M | -176.53%-166.63M | 15.44%-197.62M | -115.53%-143.19M |
Income tax | 91.24%-1.15M | 98.20%-86K | 105.51%177K | 46.91%-1.51M | 112.37%276K | -105.48%-13.08M | 90.44%-4.78M | -107.57%-3.21M | 98.19%-2.85M | -100.55%-2.23M |
Net income | 15.14%-521.96M | 9.82%-104.59M | -30.78%-213.72M | 28.95%-138.38M | 53.69%-65.28M | -219.25%-615.12M | -14.14%-115.97M | -193.21%-163.41M | -154.63%-194.78M | -127.18%-140.96M |
Net income continuous Operations | 15.14%-521.96M | 9.82%-104.59M | -30.78%-213.72M | 28.95%-138.38M | 53.69%-65.28M | -219.25%-615.12M | -14.14%-115.97M | -193.21%-163.41M | -154.63%-194.78M | -127.18%-140.96M |
Minority interest income | 0 | 0 | 0 | 0 | 0 | -56K | 0 | 0 | 0 | -56K |
Net income attributable to the parent company | 15.14%-521.96M | 9.82%-104.59M | -30.78%-213.72M | 28.95%-138.38M | 53.67%-65.28M | -219.24%-615.06M | -14.14%-115.97M | -193.21%-163.41M | -154.63%-194.78M | -127.17%-140.9M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 15.14%-521.96M | 9.82%-104.59M | -30.78%-213.72M | 28.95%-138.38M | 53.67%-65.28M | -219.24%-615.06M | -14.14%-115.97M | -193.21%-163.41M | -154.63%-194.78M | -127.17%-140.9M |
Basic earnings per share | 16.56%-3.83 | 11.63%-0.76 | -27.87%-1.56 | 29.66%-1.02 | 54.72%-0.48 | -217.99%-4.59 | -13.16%-0.86 | -192.42%-1.22 | -150.00%-1.45 | -126.97%-1.06 |
Diluted earnings per share | 16.56%-3.83 | 11.63%-0.76 | -27.87%-1.56 | 29.66%-1.02 | 54.72%-0.48 | -219.84%-4.59 | -13.16%-0.86 | -193.85%-1.22 | -150.00%-1.45 | -127.53%-1.06 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |